Mirion (MIR) Q3 2025 Earnings Transcript

Mirion Technologies posted Q3 revenue of $223.1 million, up 7.9%, with adjusted EBITDA rising 14.7% to $52.4 million and margin expansion of about 140 bps. Management raised full-year adjusted free cash flow guidance to $100 million-$115 million and highlighted accelerating nuclear power demand, including 21% adjusted nuclear orders growth and $17 million of SMR-related orders in the quarter. Offsetting positives include pressure in U.S. RTQA and delays in $110 million of government-related pipeline opportunities into 2026 due to the shutdown.

Analysis

Mirion is becoming less of a pure industrial safety supplier and more of a call option on the regulated nuclear build cycle, but the real lever is not headline reactor construction — it is installed-base monetization plus compliance adjacency. The strategic additions meaningfully widen the “sell-through” surface area: software, cybersecurity, regulatory workflow, and reactor protection systems all increase wallet share without waiting for first concrete in a new build, which should lift both order durability and mix quality over the next 12-24 months.

The market is likely underappreciating how much the current order acceleration is being front-loaded by SMR and policy workflows rather than by large utility-scale projects. That matters because these smaller, earlier-stage orders create a wider funnel of repeatable revenue, while the large projects pushed into 2026 are more lumpy and more exposed to funding/political delay. In other words, near-term upside is more likely to come from a higher-quality stream of “many small wins” than from a single mega-backlog print.

The medical segment is the offsetting variable: it is not broken, but it has become a pacing item for earnings revisions because government/funding noise can depress capex timing without actually reducing long-term demand. That creates an interesting second-order effect: if nuclear sentiment stays hot while medical merely normalizes, consensus may overstate the durability of consolidated margin expansion and understate how much of the beat is mix- and procurement-driven. The right framework is to expect beats from nuclear orders and FCF conversion, but to discount any claim that the 30% EBITDA target will be pulled forward materially by new-build mix, since that mix is structurally lower margin.

Key Decisions for Investors

• Long MIR into the Q4/order-book print over the next 4-8 weeks; the setup is for upside on bookings and FCF guidance credibility, with downside mainly if government-funded projects slip again into 2026.
• Pair trade: long MIR / short a basket of higher-beta pre-revenue nuclear names (for example, SMR proxies) over 3-6 months; MIR has revenue, cash flow, and installed-base protection, while the speculative names are more exposed to financing and timing risk.
• If already long MIR, consider financing via covered calls into the next earnings cycle; implied upside is likely capped by management’s conservative disclosure on the large-opportunity pipeline, while near-term downside is cushioned by FCF revisions.
• Avoid chasing the medical recovery story here; treat RTQA normalization as a 2026 catalyst, not a Q1 revenue bridge. If you want exposure, keep it as a lower-conviction add-on to the core nuclear thesis rather than the main driver.
• Monitor for a pullback caused by delayed large-project awards; that would be a better entry point for a 6-12 month long, because the installed-base and regulatory software mix should support multiple expansion once the market sees recurring order conversion.